SCHEMBL5225475

SCHEMBL5225475

COc1ccc(C(=O)N(C)S(=O)(=O)Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.52
CA2 P00918 4/20 0.52
CES2 O00748 1/20 0.50
CES1 P23141 1/20 0.50
HPGD P15428 4/20 0.49
KDM4E B2RXH2 1/20 0.49
TP53 P04637 2/20 0.48
LMNA P02545 1/20 0.48
GSK3B P49841 1/20 0.47
PARP1 P09874 1/20 0.47
PARP10 Q53GL7 1/20 0.47
PARP2 Q9UGN5 1/20 0.47
PARP4 Q9UKK3 1/20 0.47
ALDH1A1 P00352 3/20 0.46
MAPT P10636 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
DRD2 P14416 1/20 0.46
HSD17B1 P14061 1/20 0.46
HSD17B2 P37059 1/20 0.46
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7736889 0.84 CES2 (0.52) CA1CA2CES2CES1HPGD
SCHEMBL11212295 0.77 CES2 (0.61) CA1CA2CES2CES1HPGD
SCHEMBL1659309 0.77 HPGD (0.73) CA1CA2CES2CES1HPGD
SCHEMBL8464944 0.76 CES2 (0.59) CA1CA2CES2CES1HPGD
SCHEMBL30527863 0.75 CES2 (0.64) CA1CA2CES2CES1HPGD
SCHEMBL13412202 0.75 CES2 (0.53) CA1CA2CES2CES1HPGD
SCHEMBL11685994 0.75 CES2 (0.53) CA1CA2CES2CES1HPGD
SCHEMBL10049412 0.74 CA1 (0.59) CA1CA2CES2CES1HPGD
SCHEMBL5444945 0.74 CES2 (0.57) CA1CA2CES2CES1HPGD
SCHEMBL286256 0.74 CES2 (0.57) CA1CA2CES2CES1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254882-A1 Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same CRYSTAL GENOMICS, INC. (KR) 2007-11-01 US disclosed
EP-1778654-A1 SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME Crystalgenomics, Inc. (KR) 2007-05-02 EP disclosed
WO-2006006832-A1 SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME CRYSTALGENOMICS, INC. (KR) 2006-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254882-A1 Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same SULT2A1, SPTLC2, SGMS2 CA1 3138/4885CA2 1013/4885CES2 310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.